Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Genetically Engineered Animals
Knockout Mice
Knockout Rats
Knockin Mice
Knockin Rats
Transgenic Mice
Transgenic Rats
Model Generation Techniques
Turboknockout<sup>®</sup> Gene Targeting
ES Cell Gene Targeting
Targeted Gene Editing
Regular Transgenic
PiggyBac Transgenesis
BAC Transgenic
Research Models
HUGO-GT™ Humanized Mice
Cre Mouse Lines
Humanized Target Gene Models
Metabolic Disease Models
Ophthalmic Disease Models
Neurological Disease Models
Autoimmune Disease Models
Immunodeficient Mouse Models
Humanized Immune System Mouse Models
Oncology & Immuno-oncology Models
Covid-19 Mouse Models
MouseAtlas Model Library
Knockout Cell Line Product Catalog
Tumor Cell Line Product Catalog
AAV Standard Product Catalog
Animal Supporting Services
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
BAC Modification
Custom Cell Line Models
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Point Mutation Cell Lines
Overexpression Cell Lines
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Lentivirus Packaging
Adenovirus Packaging
CRO Services
By Therapeutic Area
Oncology
Ophthalmology
Neuroscience
Metabolic & Cardiovascular Diseases
Autoimmune & Inflammatory
By Drug Type
AI-Powered AAV Discovery
Gene Therapy
Oligonucleotide Therapy
Antibody Therapy
Cell Immunotherapy
Resources
Promotion
Events & Webinars
Newsroom
Blogs & Insights
Resource Vault
Reference Databases
Peer-Reviewed Citations
Rare Disease Data Center
AbSeek
Cell iGeneEditor™ System
OriCell
Quality
Facility Overview
Animal Health & Welfare
Health Reports
About Us
Corporate Overview
Our Partners
Careers
Contact Us
Login
Rare Diseases
Unraveling Rare Diseases: Researching Hotspot Pathogenic Mutations in Humanized Models
Cyagen Technical Content Team | June 02, 2025
Explore Ready-to-Use Mouse Models in MouseAtlas
Discover our extensive library of KO, cKO, and disease-specific mouse models. Accelerate your research with study-ready animals validated by scientists worldwide.
Explore Ready-to-Use Mouse Models in MouseAtlas
Contents
01. Understanding Hotspot Pathogenic Mutations
02. Familial Dysautonomia: ELP1 Intronic Point Mutation
03. Facioscapulohumeral Muscular Dystrophy: Abnormal DUX4 Expression

Welcome to the ‘Ten Deadly Sins of Rare Diseases’ column, where we decode the pathogenic mechanisms of rare diseases, industry research progress (e.g. gene therapy), and innovative pre-clinical strategies to drive translational research results (such as model construction and drug screening, etc.).

At Cyagen, we are a trusted provider of high-quality synthetic guide molecules used in advanced gene editing applications, supporting researchers throughout the development of innovative cell and gene therapies. In this blog, we will explore what guide molecules are, why their sequences are critical to editing efficiency and specificity, and introduce the different quality grades available—from early-stage discovery to clinical-grade delivery. Read on to discover how we can help accelerate your gene and cell therapy development programs with precision-engineered editing solutions.

Understanding Hotspot Pathogenic Mutations

Gene mutations refer to alterations in the structure or sequence of genetic material, including changes in the order or composition of nucleotide base pairs. These mutations can occur within both coding regions and non-coding regions such as promoters, introns, and splice sites.

One of the key components enabling targeted genome modification is the guide RNA molecule, which plays a critical role in directing editing enzymes to the correct genomic location. A commonly used guide format is the single guide molecule (sGuide Molecule), which can sometimes be confused with the dual-guide configuration, so let’s briefly explain the distinction.

In natural bacterial defense systems, the targeting mechanism involves two separate RNA molecules: one serves as the recognition sequence (~20 nucleotides) that matches the target DNA region, while the other acts as a structural scaffold to facilitate the binding of the complex to the editing enzyme.

The sGuide Molecule is a streamlined, engineered format in which these two RNA components are fused into a single chimeric strand. This single-guide format has become widely adopted in modern gene editing due to its simplicity and ease of customization. While guide molecules can be synthesized in vitro or expressed via plasmid or viral vectors, chemically synthesized single-guide formats typically offer superior editing performance and consistency.

Familial Dysautonomia: ELP1 Intronic Point Mutation
Familial dysautonomia (FD) is a rare inherited condition affecting your nervous system. It impacts breathing, salivating, forming tears and regulating body temperature and blood pressure. Providers diagnose FD with specific tests and genetic testing. Treatments include medications, therapy and surgery. People with FD have shorter life expectancies.
Genetic changes (mutations) cause familial dysautonomia. Both of your parents must carry a mutation in a gene called ELP1. The ELP1 gene makes a protein that helps your nervous system develop. If this gene has a mutation, problems occur with parts of your nervous system.
Facioscapulohumeral Muscular Dystrophy: Abnormal DUX4 Expression
Advances in the molecular understanding of facioscapulohumeral muscular dystrophy (FSHD) have revealed that FSHD results from epigenetic de-repression of the DUX4 gene in skeletal muscle, which encodes a transcription factor that is active in early embryonic development but is normally silenced in almost all somatic tissues. These advances also led to the identification of targets for disease-altering therapies for FSHD, as well as an improved understanding of the molecular mechanism of the disease and factors that influence its progression. Together, these developments led the FSHD research community to shift its focus towards the development of disease-modifying treatments for FSHD. This Review presents advances in the molecular and clinical understanding of FSHD, discusses the potential targeted therapies that are currently being explored, some of which are already in clinical trials, and describes progress in the development of FSHD-specific outcome measures and assessment tools for use in future clinical trials.
DUX4, a gene encoding a transcription factor involved in early embryogenesis, is located within the D4Z4 subtelomeric repeat on chromosome 4q35. In most healthy somatic tissues, DUX4 is heavily repressed by multiple genetic and epigenetic mechanisms, and its aberrant expression is linked to facioscapulohumeral muscular dystrophy (FSHD) where it has been extensively studied. Recently, DUX4 expression has been implicated in oncogenesis, although this is much less explored. In this review, we discuss multiple levels of control of DUX4 expression, including enhancer–promoter interactions, DNA methylation, histone modifications, noncoding RNAs, and telomere positioning effect. We also connect disparate data on intrachromosomal contacts involving DUX4 and emphasize the feedback loops in DUX4 regulation. Finally, we bridge data on DUX4 in FSHD and cancer and discuss prospective approaches for future FSHD therapies and the potential outcomes of DUX4 inhibition in cancer.
References
[1] Carmel I , Tal S , Vig I ,et al.Comparative analysis detects dependencies among the 5′ splice-site positions[J].RNA, 2004, 10(5):828-840.DOI:10.1261/rna.5196404.
[2] Anderson S L , Coli R , Daly I W ,et al.Familial Dysautonomia Is Caused by Mutations of the IKAP Gene[J].The American Journal of Human Genetics, 2001, 68(3):753-758.DOI:10.1086/318808.
ABOUT THE AUTHOR
Rebecca Roberts, Ph.D.
Rebecca Roberts is a molecular biologist and science writer. She loves demystifying science to the general public and has too many hobbies to be really good at any of them. When she’s not working, you can usually find her in a forest somewhere, drinking coffee, or listening to death metal.
Subscribe to Receive Updates & Promotions From Cyagen
Subscribe
* Your privacy matters to us. We never share it with third parties.
Explore More
Y Maze Behavioral Task: Studying the function of spatial learning and memory in Neuroscience research
Spinocerebellar Ataxia Type III (SCA3) Research Model—B6-hATXN3 Mice
Vision Stolen by Years - Age-related Macular Degeneration
HFD+CCl4-Induced Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Mice
Share
Top
Ready to Elevate Your Research?
Discover how Cyagen can support your research. Let’s start a conversation.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0338
Email:
animal-service@cyagen.com
service@cyagen.us
CRO Services
OncologyOphthalmologyNeuroscienceMetabolic & CardiovascularAutoimmune & InflammatoryGene TherapyAntibody Therapy
About Us
Corporate OverviewOur PartnersCareersContact Us
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest